LexaGene Holdings Inc (TSX-V:LXG, OTCQB:LXXGF) said it has entered into a purchase agreement with a veterinary hospital in Wisconsin.
In a statement, Dr Jack Regan, LexaGene's CEO and founder commented: "We are pleased to announce this sale to a veterinary hospital in Wisconsin. Once we complete our scheduled installations, we will have MiQLab Systems operating in 10 states across the US."
"Since the start of this year, our install base has increased 240% and we expect an even steeper increase in the latter part of this year," he added.
READ: LexaGene reveals MiQLab Systems sale to large US veterinary corporation
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense.
End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press 'go'.